Long‐Term Impact of Guselkumab on Skin, Sexuality, and Perceived Stigmatization in Patients With Psoriasis in Routine Clinical Practice: Week 76 Effectiveness and Safety Results From the Prospective German Multicenter G‐ <scp>EPOSS</scp> Study
Guselkumab treatment provided sustained improvements over 76 weeks in psoriasis, sexual impairment, QoL, and perceived stigmatization, irrespective of BMI, age, disease duration, sex, presence of anogenital psoriasis, or depression.
Authors
- Friedemann Taut (ORCID: https://orcid.org/0009-0003-5208-6096)
- Sascha Gerdes (ORCID: https://orcid.org/0000-0002-6667-7757)
- Alexander Otto (ORCID: https://orcid.org/0000-0002-1550-0724)
- Durdana Groß
- Dariusch Mortazawi
- Rolf Ostendorf
- Nina Trenkler
- Juliane Behrens
- Sebastian Zimmer (ORCID: https://orcid.org/0000-0002-1531-2088)
- Peter Weisenseel
- Judita Makuc
- Simmy Jacobsen
Institutions
- Krankenhaus Düren (DE)
- InLeaVe (DE)
- Hasomed (Germany) (DE)
- Johnson & Johnson (Germany) (DE)
- Klinikum Konstanz (DE)
- Dermatologikum Hamburg (DE)
- Städtische Kliniken Mönchengladbach (DE)
- Clinical Research Center Kiel (DE)
- St. Remigius Krankenhaus Opladen (DE)
Publication Details
- Journal
- The Journal of Dermatology
- Published
- 2025-08-09
- DOI
- https://doi.org/10.1111/1346-8138.17866
- Citations
- 1
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Yale University
- Cilag